Cargando…

Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?

Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results, but a lower risk of chronic kidney disease, when compared with radical nephrectomy. However, there are limited data in the literature examining the safety of NSS in the setting of metastatic RCC. To eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahait, Mohammed, Mukherji, Deborah, El-Hout, Yaser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397543/
https://www.ncbi.nlm.nih.gov/pubmed/25878408
http://dx.doi.org/10.4103/0970-1591.154300
_version_ 1782366722341208064
author Shahait, Mohammed
Mukherji, Deborah
El-Hout, Yaser
author_facet Shahait, Mohammed
Mukherji, Deborah
El-Hout, Yaser
author_sort Shahait, Mohammed
collection PubMed
description Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results, but a lower risk of chronic kidney disease, when compared with radical nephrectomy. However, there are limited data in the literature examining the safety of NSS in the setting of metastatic RCC. To evaluate the feasibility of NSS and impact on cancer-specific survival (CSS) in patients with metastatic disease, we performed a systematic review of the literature. There is ample evidence that NSS is feasible in metastatic RCC, with comparable results in terms of CSS compared with radical cytoreductive nephrectomy.
format Online
Article
Text
id pubmed-4397543
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43975432015-04-15 Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand? Shahait, Mohammed Mukherji, Deborah El-Hout, Yaser Indian J Urol Review Article Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results, but a lower risk of chronic kidney disease, when compared with radical nephrectomy. However, there are limited data in the literature examining the safety of NSS in the setting of metastatic RCC. To evaluate the feasibility of NSS and impact on cancer-specific survival (CSS) in patients with metastatic disease, we performed a systematic review of the literature. There is ample evidence that NSS is feasible in metastatic RCC, with comparable results in terms of CSS compared with radical cytoreductive nephrectomy. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4397543/ /pubmed/25878408 http://dx.doi.org/10.4103/0970-1591.154300 Text en Copyright: © Indian Journal of Urology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Shahait, Mohammed
Mukherji, Deborah
El-Hout, Yaser
Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
title Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
title_full Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
title_fullStr Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
title_full_unstemmed Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
title_short Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
title_sort partial nephrectomy for metastatic renal cell carcinoma: where do we stand?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397543/
https://www.ncbi.nlm.nih.gov/pubmed/25878408
http://dx.doi.org/10.4103/0970-1591.154300
work_keys_str_mv AT shahaitmohammed partialnephrectomyformetastaticrenalcellcarcinomawheredowestand
AT mukherjideborah partialnephrectomyformetastaticrenalcellcarcinomawheredowestand
AT elhoutyaser partialnephrectomyformetastaticrenalcellcarcinomawheredowestand